Stoke Therapeutics Inc STOK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
-
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
-
Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
-
Stoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization
-
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
-
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
-
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 64.53M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 31.67
- Price/Sales
- 50.92
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 170
Valuation
|
Metric
|
STOK
|
|---|---|
Price/Earnings (Normalized) | 31.67 |
Price/Book Value | 4.06 |
Price/Sales | 50.92 |
Price/Cash Flow | — |
Price/Earnings
STOK
Financial Strength
|
Metric
|
STOK
|
|---|---|
Quick Ratio | 7.19 |
Current Ratio | 7.69 |
Interest Coverage | — |
Quick Ratio
STOK
Profitability
|
Metric
|
STOK
|
|---|---|
Return on Assets (Normalized) | −42.61% |
Return on Equity (Normalized) | −49.10% |
Return on Invested Capital (Normalized) | −52.74% |
Return on Assets
STOK
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|H<FD@@ | LOCK|#&h# | $127B | |||
| Moderna Inc
MRNA
| LOCK|Tf>?r> | LOCK|zCW | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@W<<#! | LOCK|dZT^C | $81B | |||
| argenx SE ADR
ARGX
| LOCK|>#@<!h | LOCK|tNR | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|W@md!Z@ | LOCK|S<R | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|G?M?kd | LOCK|!Z?^? | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|f>ND$Kpj | LOCK|%B%? | $27B | |||
| Incyte Corp
INCY
| LOCK|$DSqP?^ | LOCK|&S | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|rNkqBX | LOCK|?J | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|m#w<#! | LOCK|Zl | $14B |
United States